top of page
Browse by category
Search
Vivani issues positive preclinical weight loss data for NPM-139 semaglutide implant
Vivani Medical has announced promising preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic...
BMS demonstrates superior efficacy over non-surgical treatments in managing obesity and associated metabolic disorders
A systematic review and meta-analysis of randomised clinical trials (RCTs) underscores the superior efficacy of bariatric and metabolic...
Sucralose alters brain activity related to hunger and increases appetite, especially in people with obesity
A study from the Keck School of Medicine of USC found that sucralose, a common sugar substitute, alters brain activity related to hunger...
Bioequivalence of RT-114, delivered orally via the RaniPill capsule, to subcutaneously administered PG-102
Rani Therapeutics has announced pharmacokinetic and pharmacodynamic data from a preclinical study evaluating RT-114, a GLP-1/GLP-2 dual...
Why obesity takes away the pleasure of eating
A study by scientists at the University of California, Berkeley, suggests that pleasure in eating, even eating junk food, is key to...
Medicare and other insurance should cover obesity drugs
A large majority of older Americans feel that health insurance - including Medicare - should cover anti-obesity medications, according to...
Journal Watch 26/3/2025
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Palatin's oral MC4R Agonist PL7737 receives FDA Orphan Drug Designation for obesity due to leptin receptor deficiency
Palatin Technologies has announced the FDA has granted "orphan drug" designation to PL7737, an oral treatment that activates the...
AI-powered smartphone app constructs 3D model to accurately predict body fat
Researchers from the University of Cambridge have developed a smartphone app that uses machine learning to accurately determine body...
United Biotechnology and Novo Nordisk agree license for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The United Laboratories International Holdings Limited’s (TUL) wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd....
Browse by tag
bottom of page